TitleAssociate Professor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65. PMID: 25502429; PMCID: PMC4529067.
      Citations: 6     Fields:    Translation:Humans
    2. Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, Blake P, Chirina P, Oh Jeong J, Lim H, Goy A, Pecora A, Suh KS. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 2014 Dec 05; 7:109. PMID: 25477184; PMCID: PMC4271347.
      Citations: 14     Fields:    Translation:HumansCells
    3. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93. PMID: 24743243; PMCID: PMC4058356.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    4. Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48. PMID: 24709487; PMCID: PMC4098779.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    5. Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer. Clin Cancer Res. 2014 May 15; 20(10):2740-50. PMID: 24634380; PMCID: PMC4024372.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    6. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res. 2014 Apr 01; 20(7):1846-55. PMID: 24486585; PMCID: PMC3975695.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    7. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43. PMID: 24100628; PMCID: PMC3852199.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    8. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95. PMID: 24062525; PMCID: PMC3787907.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    9. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406; PMCID: PMC3809091.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    10. Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91. PMID: 23321064; PMCID: PMC3712785.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    11. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11. PMID: 23200915; PMCID: PMC3645276.
      Citations: 14     Fields:    Translation:HumansCells
    12. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):538-43. PMID: 22922531; PMCID: PMC3568489.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    13. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41. PMID: 22895067; PMCID: PMC3461810.
      Citations: 8     Fields:    Translation:HumansCells
    14. Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9. PMID: 22776561; PMCID: PMC3498611.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    15. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4. PMID: 22710075; PMCID: PMC3748717.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    16. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res. 2012 Aug 01; 18(15):4114-21. PMID: 22693353; PMCID: PMC3638880.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    17. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8. PMID: 22335738; PMCID: PMC3296780.
      Citations: 316     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    18. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des. 2012; 18(19):2713-9. PMID: 22390757; PMCID: PMC3740204.
      Citations: 7     Fields:    Translation:Humans
    19. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9. PMID: 21795478; PMCID: PMC3174342.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    20. Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010 Dec; 1(6):277-90. PMID: 21761359; PMCID: PMC3199131.
      Citations: 41     Fields:    Translation:HumansAnimals
    21. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713; PMCID: PMC3062960.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    22. Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011 Jan; 120(1):113-20. PMID: 21056906; PMCID: PMC3004216.
      Citations: 43     Fields:    Translation:HumansCells
    23. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97. PMID: 20708159; PMCID: PMC2923653.
      Citations: 201     Fields:    Translation:AnimalsCells
    24. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23. PMID: 20389021; PMCID: PMC2860925.
      Citations: 132     Fields:    Translation:HumansAnimalsCells
    25. Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010-2011; 8(4-5):231-51. PMID: 22045356; PMCID: PMC4143980.
      Citations: 8     Fields:    Translation:Humans
    26. Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009 Oct; 201(4):367.e1-6. PMID: 19608149.
      Citations: 5     Fields:    Translation:HumansCells
    27. Jaishuen A, Jimenez C, Sirisabya N, Li Y, Zheng H, Hu W, Urbauer DL, Kavanagh JJ. Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients. Int J Gynecol Cancer. 2009 Feb; 19(2):178-85. PMID: 19395991.
      Citations: 2     Fields:    Translation:Humans
    28. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9. PMID: 19110234.
      Citations: 35     Fields:    Translation:HumansCells
    29. Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W. Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov; 3(3):162-77. PMID: 18991785; PMCID: PMC3039426.
      Citations: 2     Fields:    Translation:HumansAnimals
    30. Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S67-71. PMID: 18533239.
      Citations: 12     Fields:    Translation:Humans
    31. Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82. PMID: 18509599.
      Citations: 2     Fields:    Translation:HumansCells
    32. Zhang A, Chen G, Meng L, Wang Q, Hu W, Xi L, Gao Q, Wang S, Zhou J, Xu G, Ma D. Antisense-Snail transfer inhibits tumor metastasis by inducing E-cadherin expression. Anticancer Res. 2008 Mar-Apr; 28(2A):621-8. PMID: 18507000.
      Citations: 9     Fields:    Translation:AnimalsCells
    33. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):600-14. PMID: 17894799.
      Citations: 14     Fields:    Translation:Humans
    34. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80. PMID: 17512575.
      Citations: 4     Fields:    Translation:Humans
    35. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):325-38. PMID: 17362310.
      Citations: 19     Fields:    Translation:Humans
    36. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):739-63. PMID: 17309673.
      Citations: 15     Fields:    Translation:Humans
    37. Melichar B, Patenia R, Gallardo S, Hu W, Freedman RS, Melicharov? K. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol. 2007 Mar; 104(3):707-13. PMID: 17166566.
      Citations: 8     Fields:    Translation:HumansCells
    38. Fu S, Kavanagh JJ, Hu W, Bast RC. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32. PMID: 17009963.
      Citations: 6     Fields:    Translation:Humans
    39. Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun; 6(4):333-63. PMID: 16848724.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    40. Fu S, Hu W, Kavanagh JJ, Bast RC. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85. PMID: 16441230.
      Citations: 11     Fields:    Translation:HumansAnimals
    41. Kim HG, Yamal JM, Xu XC, Hu W, Boiko I, Linares A, Vlastos AT, Atkinson EN, Malpica A, Hittelman WN, Follen M. Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial. Gynecol Oncol. 2005 Dec; 99(3 Suppl 1):S32-7. PMID: 16154183.
      Citations: 1     Fields:    Translation:HumansCells
    42. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res. 2005 Jan 01; 11(1):113-22. PMID: 15671535.
      Citations: 37     Fields:    Translation:HumansCells
    43. Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res. 2005; 15(1):49-57. PMID: 15839305.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    44. Hu W, Wu W, Kobayashi R, Kavanagh JJ. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep. 2004 Nov; 6(6):456-62. PMID: 15485615.
      Citations: 1     Fields:    Translation:Humans
    45. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004 Oct; 3(10):1249-62. PMID: 15486192.
      Citations: 44     Fields:    Translation:HumansCells
    46. Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, Wang S, Zhou J, Hu W, Ma D. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol. 2004 Jul; 130(7):423-8. PMID: 15156398.
      Citations: 21     Fields:    Translation:HumansCells
    47. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol. 2004 Apr; 93(1):149-54. PMID: 15047229.
      Citations: 22     Fields:    Translation:HumansCells
    48. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75. PMID: 14628071.
      Citations: 43     Fields:    Translation:HumansCells
    49. Xi L, Hu W, Meng L, Zhou J, Lu Y, Wang C, Ma D. Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer. J Huazhong Univ Sci Technolog Med Sci. 2004; 24(1):62-5. PMID: 15165118.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    50. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003 Dec; 4(12):721-9. PMID: 14662428.
      Citations: 119     Fields:    Translation:HumansCells
    51. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003 Nov; 17(11):2081-9. PMID: 12970762.
      Citations: 37     Fields:    Translation:HumansCells
    52. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34. PMID: 14675307.
      Citations: 10     Fields:    Translation:HumansCells
    53. Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7. PMID: 14586557.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    54. Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ. Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics. 2003 Oct; 3(10):1904-11. PMID: 14625852.
      Citations: 12     Fields:    Translation:HumansCells
    55. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Kavanagh J, Steger M, Schulz KD, V?lker P, Emons G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003 Sep; 90(3):552-9. PMID: 13678723.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    56. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, Siddik ZH. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol. 2003 Oct; 129(10):549-55. PMID: 14513369.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    57. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003 Jul 15; 63(14):4174-80. PMID: 12874023.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    58. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res. 2003 Mar; 9(3):1161-70. PMID: 12631622.
      Citations: 45     Fields:    Translation:HumansCells
    59. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003 Feb; 9(2):845-52. PMID: 12576458.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    60. Wu W, Hu W, Kavanagh JJ. Proteomics in cancer research. Int J Gynecol Cancer. 2002 Sep-Oct; 12(5):409-23. PMID: 12366655.
      Citations: 7     Fields:    Translation:Humans
    61. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002 Sep; 16(9):1713-24. PMID: 12200686.
      Citations: 167     Fields:    Translation:HumansAnimalsCells
    62. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002 Aug; 118(2):521-34. PMID: 12139741.
      Citations: 52     Fields:    Translation:HumansCells
    63. Hu W, Wu W, Yeung SC, Freedman RS, Kavanagh JJ, Verschraegen CF. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res. 2002 Mar-Apr; 22(2A):665-72. PMID: 12014635.
      Citations: 7     Fields:    Translation:HumansCells
    64. Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ. Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. Int J Gynecol Cancer. 2002 Mar-Apr; 12(2):202-7. PMID: 11975681.
      Citations: 2     Fields:    Translation:HumansCells
    65. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 2002; 19(4):319-26. PMID: 12090472.
      Citations: 61     Fields:    Translation:HumansCells
    66. Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, Hu W, Vincent M, Nelson T, Levenback C, Community Clinical Oncology Program. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33. PMID: 11745287.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    67. Hu W, Wu W, Nash MA, Freedman RS, Kavanagh JJ, Verschraegen CF. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res. 2000 Mar-Apr; 20(2A):729-33. PMID: 10810347.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    68. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis. 2000; 18(1):83-8. PMID: 11206843.
      Citations: 36     Fields:    Translation:HumansCells
    69. Boiko IV, Mitchell MF, Hu W, Pandey DK, Mathevet P, Malpica A, Hittelman WN. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res. 1998 Jun; 4(6):1383-91. PMID: 9626454.
      Citations: 4     Fields:    Translation:Humans
    70. Boiko IV, Mitchell MF, Pandey DK, White RA, Hu W, Malpica A, Nishioka K, Boone CW, Atkinson EN, Hittelman WN. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1997 Oct; 6(10):849-55. PMID: 9332769.
      Citations:    Fields:    Translation:Humans
    71. Hu W, Mitchell MF, Boiko IV, Linares A, Kim HG, Malpica A, Tortolero-Luna G, Hittelman WN. Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):711-8. PMID: 9298579.
      Citations: 1     Fields:    Translation:Humans
    72. Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells. Frontiers in Oncology. 3 MAR.
    73. Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase. Oncology Letters. 6:339-346.
    74. Stress related neuroendocrine influences in ovarian cancer. Current Cancer Therapy Reviews. 8:100-109.
    75. Proteomics in gynecologic malignancies. American Journal of Cancer. 5:299-317.
    76. PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Molecular Cancer Therapeutics. 14:1466-1475.
    77. Determination of progesterone receptor by chemil uminescent enzyme immunoassay. Journal of Huazhong University of Science and Technology - Medical Science. 23:60-61.
    78. Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth. Molecular Cancer Therapeutics. 15:1344-1352.
    79. Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias. Blood. 96.
    80. Erratum. Gynecologic Oncology. 130:252-253.
    81. XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.
    82. Clinical effect of four-combined therapy on cancer. Tumor. 28:167-169.
    83. Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.
    84. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.
    85. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research. 22:1713-1724.
    86. rIFN-γ-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. Journal of Translational Medicine. 1.
    87. Apoptosis-inducing anticancer drugs in clinical trials. 341-364.
    88. Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer. Molecular Cancer Therapeutics. 15:2894-2904.
    HU's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (409)
    Co-Authors (48)
    Similar People (60)
    Same Department Expand Description